By sharing her own experiences and helping athletes see their value, Anne has truly become the ultimate “coach.” When she ...

I had a symptom of colon cancer and family history, so I got a colonoscopy. It was expensive, and insurance was a nightmare, ...

Madison-based Exact Sciences' story illustrates that basic research — combined with hard work, strong teams and enough money ...

Other colon cancer screening tests currently under development are at-home blood sample tests. Their low level of accuracy means they are currently not recommended for use in place of FOBT, FIT ...

BofA analysts review the promise and limits of AI in precision medicine, highlighting key players like Tempus, Guardant, and ...

In Cannes last week, creative leaders from Area 23, The Bloc, Eversana and MMC joined MM+M in the Palais basement to walk the ...

When Brenda Harbin’s husband, Joe, was preparing to take a Cologuard screening test for colon cancer in late April 2017, she ...

Cologuard is an at-home cancer-screening product. Developers say it detects 94 percent of colon cancer, the same percentage as a colonoscopy.

The ruling ensures continued coverage, without patient cost-sharing, of services including BRCA testing and colorectal cancer screening, potentially impacting firms like Exact Sciences.

Of the 30 companies included in the list, 24 firms saw their stock prices rise, four saw their share prices decline, and two saw their stock prices remain flat.